Description
Name: GLP-1 and GIP Dual Agonist (TZ)
Sequence: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Ahx-Ahx-Lys-NH₂ (C20 fatty diacid moiety attached via linker)
Molecular Formula: C₂₂₅H₃₆₃N₄₈O₆₈
Molecular Weight: ≈ 4813.55 g/mol
CAS Registry Number: 2023788-19-2
Dual Agonist (GLP-1 / GIP) – COMPREHENSIVE RESEARCH PEPTIDE FOR INCRETIN AND DUAL RECEPTOR SIGNALING STUDIES
Scientific Overview of Dual Agonist (GLP-1 / GIP)
Dual Agonist (GLP-1 / GIP) is a synthetic dual receptor agonist peptide that acts on both the Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) receptors. It is structurally based on the native GIP sequence, modified to include fatty acid side-chain conjugation for increased plasma stability and receptor binding persistence.
In preclinical and mechanistic studies, Dual Agonist (GLP-1 / GIP) has been investigated for its role in metabolic and endocrine research models, focusing on:
• Dual Receptor Activation – exploration of concurrent GLP-1R and GIPR binding and downstream cAMP pathway signaling (Frias et al., 2018)
• Metabolic Pathway Integration – study of peptide-mediated modulation of glucose metabolism and lipid utilization (Coskun et al., 2018)
• Structural Optimization and Acylation Modifications – evaluation of long-chain fatty acid conjugation and receptor selectivity enhancements (Willard et al., 2020)
This peptide serves as a key research tool for examining incretin biology, dual receptor dynamics, and peptide engineering aimed at understanding complex metabolic signaling processes.
*This peptide is intended solely for laboratory research use. It is not approved for human consumption or therapeutic application.
COA for this item
Reviews
There are no reviews yet.